Guangzhou Wondfo Biotech Co. Ltd.
About
Wondfo is ramping up neutralizing antibody, antigen and PCR tests to address the evolving demands for COVID-19 testing globally. As countries draw up plans to deal with the new wave of infections amidst the pandemic while vaccination programmes are rolled out, Wondfo remains resolute and agile to provide healthcare authorities with the specific tests they need to apply appropriate testing strategies that can help bring the pandemic under control.
Testing is crucial as it informs effective mass intervention programmes that can also minimise disruption to economic activities. However, during a pandemic of such size and scale, it is difficult for countries to determine a perfect testing strategy, as there is no one-size-fits-all approach. It is not only impossible for countries to rely on one 'gold standard' test, they cannot adopt the exact same strategies due to varying demographics, infrastructure, cultural attitudes, and economic capacity.
Testing is a nuanced process. When determining which type of test to use, key aspects such as changes in the course of the disease and the nature of the tests available need to be incorporated.
About Wondfo Guangzhou Wondfo Biotech Co., Ltd., has been that specialize in the R&D, production, sales and repair of point-of-care testing (POCT) product and providing customers with skilled speedy identification and chronic unwellness management solutions since based in 1992. Wondfo currently has over 4000 staff and a large vary of product for the speedy identification of vas diseases, inflammation, tumor, infectious diseases, drug abuse, pregnancy, and so on, wide sold-out to 140+ countries and regions.